- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
SMS Pharmaceuticals has announced a board meeting on June 9 to review the financial results for the quarter and half-year. FY25 PAT rose 39% YoY to ₹69.14 Cr, supported by volume growth, cost efficiencies, and backward integration, boosting EBITDA margin to 18%. Revenues increased 10% to ₹782.75 Cr, driven by strong demand in ARVs, anti-epileptics, and ibuprofen. Backward integration for key APIs will start commercial production by Q2 FY26, reducing costs. A ₹250 Cr Capex is planned to expand high-value API capacity and the CMO business. FY26 targets 20% revenue growth and 20% EBITDA margin.